Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute

N/ACompletedNCT01938417

University of Lausanne Hospitals12 enrolled

Overview

This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Orthopedic Operations

Interventions

tobramycinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (\> or =18 years old) patients * Treatment with Osteoset® T Exclusion Criteria: * Intravenous tobramycin

Outcomes

Primary Outcomes

Measurement of systemic tobramycin concentration

Develop a population pharmacokinetic model for tobramycin in patients treated with an active calcium sulfate bone substitute and to predict tobramycin systemic exposure under various dose and renal function levels.

Time frame: within 10 days after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.